Concepts (145)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Antibodies, Viral | 13 | 2024 | 3156 | 1.170 |
Why?
|
Immunization, Secondary | 3 | 2024 | 367 | 1.010 |
Why?
|
Meningococcal Infections | 2 | 2023 | 77 | 0.900 |
Why?
|
Meningococcal Vaccines | 2 | 2023 | 94 | 0.880 |
Why?
|
Vaccines | 4 | 2022 | 844 | 0.750 |
Why?
|
Neisseria meningitidis, Serogroup A | 1 | 2020 | 6 | 0.720 |
Why?
|
Influenza, Human | 5 | 2024 | 1521 | 0.660 |
Why?
|
Immunoglobulin G | 6 | 2024 | 4544 | 0.650 |
Why?
|
Human Experimentation | 1 | 2019 | 123 | 0.620 |
Why?
|
Orthomyxoviridae | 1 | 2019 | 149 | 0.590 |
Why?
|
Influenza Vaccines | 5 | 2024 | 768 | 0.570 |
Why?
|
Viruses | 1 | 2021 | 375 | 0.560 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2023 | 5671 | 0.520 |
Why?
|
Systems Biology | 1 | 2019 | 481 | 0.500 |
Why?
|
Vaccines, Synthetic | 4 | 2024 | 616 | 0.440 |
Why?
|
Hematologic Neoplasms | 1 | 2024 | 1896 | 0.400 |
Why?
|
Pandemics | 6 | 2024 | 8654 | 0.370 |
Why?
|
Host-Pathogen Interactions | 1 | 2019 | 1459 | 0.350 |
Why?
|
Hepatitis C, Chronic | 2 | 2015 | 1032 | 0.350 |
Why?
|
Hepatitis B virus | 1 | 2013 | 528 | 0.330 |
Why?
|
Hepatitis B, Chronic | 1 | 2013 | 410 | 0.310 |
Why?
|
Antibodies, Neutralizing | 6 | 2024 | 1943 | 0.300 |
Why?
|
Adenine | 1 | 2013 | 987 | 0.280 |
Why?
|
Antiviral Agents | 3 | 2014 | 3060 | 0.270 |
Why?
|
Vaccines, Inactivated | 1 | 2024 | 179 | 0.220 |
Why?
|
Organic Chemicals | 1 | 2024 | 210 | 0.220 |
Why?
|
Vaccination | 4 | 2024 | 3384 | 0.210 |
Why?
|
Aluminum Hydroxide | 1 | 2022 | 54 | 0.200 |
Why?
|
Immune Evasion | 2 | 2022 | 363 | 0.190 |
Why?
|
Lymphopenia | 1 | 2023 | 281 | 0.190 |
Why?
|
Toxoplasmosis | 1 | 2021 | 94 | 0.180 |
Why?
|
Antibody Formation | 2 | 2022 | 1395 | 0.180 |
Why?
|
Humans | 39 | 2024 | 761504 | 0.170 |
Why?
|
Toxoplasma | 1 | 2021 | 157 | 0.170 |
Why?
|
Immunity, Humoral | 1 | 2024 | 606 | 0.170 |
Why?
|
Immunocompromised Host | 1 | 2024 | 856 | 0.160 |
Why?
|
Health Priorities | 1 | 2021 | 374 | 0.160 |
Why?
|
AIDS Vaccines | 1 | 2024 | 896 | 0.150 |
Why?
|
Africa South of the Sahara | 1 | 2020 | 744 | 0.140 |
Why?
|
Viral Vaccines | 1 | 2022 | 596 | 0.140 |
Why?
|
Klebsiella Infections | 1 | 2018 | 146 | 0.130 |
Why?
|
Saliva | 1 | 2020 | 828 | 0.130 |
Why?
|
Hepacivirus | 2 | 2014 | 1336 | 0.130 |
Why?
|
Klebsiella pneumoniae | 1 | 2018 | 250 | 0.130 |
Why?
|
Seasons | 1 | 2021 | 1520 | 0.120 |
Why?
|
Immunoglobulin A | 3 | 2023 | 978 | 0.120 |
Why?
|
Hemagglutination Inhibition Tests | 2 | 2024 | 85 | 0.110 |
Why?
|
Squalene | 2 | 2024 | 35 | 0.110 |
Why?
|
Polysorbates | 2 | 2024 | 44 | 0.110 |
Why?
|
Sjogren's Syndrome | 1 | 2015 | 237 | 0.110 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2018 | 587 | 0.110 |
Why?
|
HIV Infections | 3 | 2024 | 17351 | 0.110 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8002 | 0.100 |
Why?
|
Middle Aged | 10 | 2024 | 220895 | 0.100 |
Why?
|
Hematologic Diseases | 1 | 2015 | 496 | 0.100 |
Why?
|
Drug Discovery | 1 | 2019 | 1051 | 0.090 |
Why?
|
B-Lymphocytes | 1 | 2024 | 4758 | 0.090 |
Why?
|
Disease Outbreaks | 1 | 2020 | 1749 | 0.090 |
Why?
|
Sensitivity and Specificity | 2 | 2023 | 14666 | 0.080 |
Why?
|
Viremia | 1 | 2013 | 707 | 0.080 |
Why?
|
Cross Reactions | 2 | 2022 | 817 | 0.080 |
Why?
|
Aged | 5 | 2024 | 169289 | 0.080 |
Why?
|
Metabolic Diseases | 1 | 2015 | 683 | 0.080 |
Why?
|
Male | 10 | 2024 | 360804 | 0.080 |
Why?
|
Adult | 8 | 2024 | 221177 | 0.070 |
Why?
|
Adjuvants, Immunologic | 2 | 2024 | 1036 | 0.070 |
Why?
|
Interferon-alpha | 1 | 2012 | 921 | 0.070 |
Why?
|
Lymphangioleiomyomatosis | 1 | 2009 | 201 | 0.070 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10209 | 0.070 |
Why?
|
Interleukins | 1 | 2012 | 782 | 0.070 |
Why?
|
Immunity, Cellular | 1 | 2013 | 1560 | 0.070 |
Why?
|
Immunoglobulin M | 2 | 2023 | 1527 | 0.070 |
Why?
|
Attitude | 2 | 2022 | 775 | 0.070 |
Why?
|
Skin Diseases | 1 | 2015 | 1094 | 0.070 |
Why?
|
T-Lymphocytes | 1 | 2024 | 10194 | 0.070 |
Why?
|
Lymphoma | 1 | 2015 | 1901 | 0.070 |
Why?
|
Female | 9 | 2024 | 392644 | 0.060 |
Why?
|
Hepatocytes | 1 | 2012 | 1233 | 0.060 |
Why?
|
Kidney Diseases | 1 | 2015 | 2091 | 0.060 |
Why?
|
Rare Diseases | 1 | 2009 | 622 | 0.060 |
Why?
|
alpha-Tocopherol | 1 | 2024 | 126 | 0.060 |
Why?
|
Viral Load | 1 | 2013 | 3332 | 0.060 |
Why?
|
United States Food and Drug Administration | 2 | 2022 | 1664 | 0.050 |
Why?
|
Autoimmune Diseases | 1 | 2015 | 2244 | 0.050 |
Why?
|
Immunization Schedule | 1 | 2024 | 227 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3084 | 0.050 |
Why?
|
United States | 5 | 2024 | 72334 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3204 | 0.050 |
Why?
|
Vaccines, Conjugate | 1 | 2023 | 328 | 0.050 |
Why?
|
Patient Participation | 1 | 2009 | 1444 | 0.040 |
Why?
|
Public-Private Sector Partnerships | 1 | 2021 | 122 | 0.040 |
Why?
|
Retrospective Studies | 3 | 2024 | 80636 | 0.040 |
Why?
|
Lung Diseases | 1 | 2009 | 1909 | 0.040 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7407 | 0.040 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2013 | 3080 | 0.040 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2013 | 4580 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2013 | 12341 | 0.040 |
Why?
|
Drug Combinations | 1 | 2024 | 2048 | 0.040 |
Why?
|
Cryoelectron Microscopy | 1 | 2022 | 650 | 0.040 |
Why?
|
Health Personnel | 2 | 2022 | 3335 | 0.040 |
Why?
|
Influenza A virus | 1 | 2021 | 458 | 0.040 |
Why?
|
Antibodies, Bacterial | 1 | 2023 | 1469 | 0.040 |
Why?
|
Crystallography, X-Ray | 1 | 2022 | 1990 | 0.040 |
Why?
|
Immunization | 1 | 2021 | 1228 | 0.030 |
Why?
|
Patient Selection | 2 | 2024 | 4244 | 0.030 |
Why?
|
RNA, Messenger | 2 | 2021 | 12795 | 0.030 |
Why?
|
Water | 1 | 2022 | 1411 | 0.030 |
Why?
|
HIV-1 | 1 | 2013 | 6863 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2018 | 15631 | 0.030 |
Why?
|
Epitopes | 1 | 2022 | 2503 | 0.030 |
Why?
|
Polysaccharides | 1 | 2022 | 1014 | 0.030 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
Prospective Studies | 2 | 2023 | 54425 | 0.030 |
Why?
|
Life Cycle Stages | 1 | 2014 | 160 | 0.030 |
Why?
|
Physician's Role | 1 | 2020 | 917 | 0.030 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5336 | 0.030 |
Why?
|
Craniotomy | 1 | 2018 | 741 | 0.030 |
Why?
|
Evolution, Molecular | 1 | 2022 | 1886 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2018 | 1834 | 0.030 |
Why?
|
Neoplasms | 1 | 2021 | 22170 | 0.030 |
Why?
|
Models, Molecular | 1 | 2022 | 5439 | 0.020 |
Why?
|
Boston | 1 | 2024 | 9326 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2021 | 2759 | 0.020 |
Why?
|
Risk Factors | 3 | 2022 | 74206 | 0.020 |
Why?
|
Protein Binding | 1 | 2022 | 9351 | 0.020 |
Why?
|
Interferons | 1 | 2012 | 706 | 0.020 |
Why?
|
Respiration, Artificial | 1 | 2018 | 2628 | 0.020 |
Why?
|
Young Adult | 2 | 2024 | 59243 | 0.020 |
Why?
|
North America | 1 | 2009 | 1276 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2020 | 12974 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6310 | 0.010 |
Why?
|
Liver Cirrhosis | 1 | 2014 | 1935 | 0.010 |
Why?
|
Child | 2 | 2022 | 80153 | 0.010 |
Why?
|
Genotype | 1 | 2014 | 12990 | 0.010 |
Why?
|
Time Factors | 1 | 2021 | 39967 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 26125 | 0.010 |
Why?
|
Cell Line | 1 | 2012 | 15601 | 0.010 |
Why?
|
Prevalence | 1 | 2014 | 15732 | 0.010 |
Why?
|
Mutation | 1 | 2022 | 30052 | 0.010 |
Why?
|
Mice | 1 | 2022 | 81525 | 0.010 |
Why?
|
Research Design | 1 | 2009 | 6180 | 0.010 |
Why?
|
Adolescent | 1 | 2021 | 88319 | 0.010 |
Why?
|
Age Factors | 1 | 2009 | 18395 | 0.010 |
Why?
|
Health Services Accessibility | 1 | 2009 | 5440 | 0.010 |
Why?
|
Animals | 1 | 2022 | 168459 | 0.010 |
Why?
|
Concepts
(145)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(74)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_